<span class="anchor" id="L01A"></span>L01A Alkylating agents
<span class="anchor" id="L01AA"></span>L01AA Nitrogen mustard analogues
:L01AA01 Cyclophosphamide
:L01AA02 Chlorambucil
:L01AA03 Melphalan
:L01AA05 Chlormethine
:L01AA06 Ifosfamide
:L01AA07 Trofosfamide
:L01AA08 Prednimustine
:L01AA09 Bendamustine
:L01AA10 Melphalan flufenamide
<span class="anchor" id="L01AB"></span>L01AB Alkyl sulfonates
:L01AB01 Busulfan
:L01AB02 Treosulfan
:L01AB03 Mannosulfan
<span class="anchor" id="L01AC"></span>L01AC Ethylene imines
:L01AC01 Thiotepa
:L01AC02 Triaziquone
:L01AC03 Carboquone
<span class="anchor" id="L01AD"></span>L01AD Nitrosoureas
:L01AD01 Carmustine
:L01AD02 Lomustine
:L01AD03 Semustine
:L01AD04 Streptozocin
:L01AD05 Fotemustine
:L01AD06 Nimustine
:L01AD07 Ranimustine
:L01AD08 Uramustine
<span class="anchor" id="L01AG"></span>L01AG Epoxides
:L01AG01 Etoglucid
<span class="anchor" id="L01AX"></span>L01AX Other alkylating agents
:L01AX01 Mitobronitol
:L01AX02 Pipobroman
:L01AX03 Temozolomide
:L01AX04 Dacarbazine
<span class="anchor" id="L01B"></span>L01B Antimetabolites
<span class="anchor" id="L01BA"></span>L01BA Folic acid analogues
:L01BA01 Methotrexate
:L01BA03 Raltitrexed
:L01BA04 Pemetrexed
:L01BA05 Pralatrexate
<span class="anchor" id="L01BB"></span>L01BB Purine analogues
:L01BB02 Mercaptopurine
:L01BB03 Tioguanine
:L01BB04 Cladribine
:L01BB05 Fludarabine
:L01BB06 Clofarabine
:L01BB07 Nelarabine
:QL01BB90 Rabacfosadine
<span class="anchor" id="L01BC"></span>L01BC Pyrimidine analogues
:L01BC01 Cytarabine
:L01BC02 Fluorouracil
:L01BC03 Tegafur
:L01BC04 Carmofur
:L01BC05 Gemcitabine
:L01BC06 Capecitabine
:L01BC07 Azacitidine
:L01BC08 Decitabine
:L01BC09 Floxuridine
:L01BC52 Fluorouracil, combinations
:L01BC53 Tegafur, combinations
:L01BC58 Decitabine, combinations
:L01BC59 Trifluridine, combinations
<span class="anchor" id="L01C"></span>L01C Plant alkaloids and other natural products
<span class="anchor" id="L01CA"></span>L01CA Vinca alkaloids and analogues
:L01CA01 Vinblastine
:L01CA02 Vincristine
:L01CA03 Vindesine
:L01CA04 Vinorelbine
:L01CA05 Vinflunine
:L01CA06 Vintafolide
<span class="anchor" id="L01CB"></span>L01CB Podophyllotoxin derivatives
:L01CB01 Etoposide
:L01CB02 Teniposide
<span class="anchor" id="L01CC"></span>L01CC Colchicine derivatives
:L01CC01 Demecolcine
<span class="anchor" id="L01CD"></span>L01CD Taxanes
:L01CD01 Paclitaxel
:L01CD02 Docetaxel
:L01CD03 Paclitaxel poliglumex
:L01CD04 Cabazitaxel
:L01CD51 Paclitaxel and encequidar
<span class="anchor" id="L01CE"></span>L01CE Topoisomerase 1 (TOP1) inhibitors
:L01CE01 Topotecan
:L01CE02 Irinotecan
:L01CE03 Etirinotecan pegol
:L01CE04 Belotecan
<span class="anchor" id="L01CX"></span>L01CX Other plant alkaloids and natural products
:L01CX01 Trabectedin
<span class="anchor" id="L01D"></span>L01D Cytotoxic antibiotics and related substances
<span class="anchor" id="L01DA"></span>L01DA Actinomycines
:L01DA01 Dactinomycin
<span class="anchor" id="L01DB"></span>L01DB Anthracyclines and related substances
:L01DB01 Doxorubicin
:L01DB02 Daunorubicin
:L01DB03 Epirubicin
:L01DB04 Aclarubicin
:L01DB05 Zorubicin
:L01DB06 Idarubicin
:L01DB07 Mitoxantrone
:L01DB08 Pirarubicin
:L01DB09 Valrubicin
:L01DB10 Amrubicin
:L01DB11 Pixantrone
<span class="anchor" id="L01DC"></span>L01DC Other cytotoxic antibiotics
:L01DC01 Bleomycin
:L01DC02 Plicamycin
:L01DC03 Mitomycin
:L01DC04 Ixabepilone
:L01DC05 Utidelone
<span class="anchor" id="L01E"></span>L01E Protein kinase inhibitors
<span class="anchor" id="L01EA"></span>L01EA BCR-ABL tyrosine kinase inhibitors
:L01EA01 Imatinib
:L01EA02 Dasatinib
:L01EA03 Nilotinib
:L01EA04 Bosutinib
:L01EA05 Ponatinib
:L01EA06 Asciminib
<span class="anchor" id="L01EB"></span>L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
:L01EB01 Gefitinib
:L01EB02 Erlotinib
:L01EB03 Afatinib
:L01EB04 Osimertinib
:L01EB05 Rociletinib
:L01EB06 Olmutinib
:L01EB07 Dacomitinib
:L01EB08 Icotinib
:L01EB09 Lazertinib
:L01EB10 Mobocertinib
:L01EB11 Aumolertinib
:L01EB12 Firmonertinib
<span class="anchor" id="L01EC"></span>L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
:L01EC01 Vemurafenib
:L01EC02 Dabrafenib
:L01EC03 Encorafenib
:L01EC04 Tovorafenib
<span class="anchor" id="L01ED"></span>L01ED Anaplastic lymphoma kinase (ALK) inhibitors
:L01ED01 Crizotinib
:L01ED02 Ceritinib
:L01ED03 Alectinib
:L01ED04 Brigatinib
:L01ED05 Lorlatinib
<span class="anchor" id="L01EE"></span>L01EE Mitogen-activated protein kinase (MEK) inhibitors
:L01EE01 Trametinib
:L01EE02 Cobimetinib
:L01EE03 Binimetinib
:L01EE04 Selumetinib
:L01EE05 Mirdametinib
:L01EE06 Tunlametinib
<span class="anchor" id="L01EF"></span>L01EF Cyclin-dependent kinase (CDK) inhibitors
:L01EF01 Palbociclib
:L01EF02 Ribociclib
:L01EF03 Abemaciclib
<span class="anchor" id="L01EG"></span>L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
:L01EG01 Temsirolimus
:L01EG02 Everolimus
:L01EG03 Ridaforolimus
:L01EG04 Sirolimus
<span class="anchor" id="L01EH"></span>L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
:L01EH01 Lapatinib
:L01EH02 Neratinib
:L01EH03 Tucatinib
:L01EH04 Zongertinib
:L01EH05 Mifanertinib
:L01EH06 Sevabertinib
<span class="anchor" id="L01EJ"></span>L01EJ Janus-associated kinase (JAK) inhibitors
:L01EJ01 Ruxolitinib
:L01EJ02 Fedratinib
:L01EJ03 Pacritinib
:L01EJ04 Momelotinib
<span class="anchor" id="L01EK"></span>L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
:L01EK01 Axitinib
:L01EK02 Cediranib
:L01EK03 Tivozanib
:L01EK04 Fruquintinib
:L01EK05 Rivoceranib
<span class="anchor" id="L01EL"></span>L01EL Bruton's tyrosine kinase (BTK) inhibitors
:L01EL01 Ibrutinib
:L01EL02 Acalabrutinib
:L01EL03 Zanubrutinib
:L01EL04 Orelabrutinib
:L01EL05 Pirtobrutinib
:L01EL06 Tirabrutinib
<span class="anchor" id="L01EM"></span>L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
:L01EM01 Idelalisib
:L01EM02 Copanlisib
:L01EM03 Alpelisib
:L01EM04 Duvelisib
:L01EM05 Parsaclisib
:L01EM06 Inavolisib
<span class="anchor" id="L01EN"></span>L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
:L01EN01 Erdafitinib
:L01EN02 Pemigatinib
:L01EN03 Infigratinib
:L01EN04 Futibatinib
<span class="anchor" id="L01EP"></span>L01EP Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors
:L01EP01 Capmatinib
:L01EP02 Tepotinib
:L01EP03 Savolitinib
<span class="anchor" id="L01EX"></span>L01EX Other protein kinase inhibitors
:L01EX01 Sunitinib
:L01EX02 Sorafenib
:L01EX03 Pazopanib
:L01EX04 Vandetanib
:L01EX05 Regorafenib
:L01EX06 Masitinib
:L01EX07 Cabozantinib
:L01EX08 Lenvatinib
:L01EX09 Nintedanib
:L01EX10 Midostaurin
:L01EX11 Quizartinib
:L01EX12 Larotrectinib
:L01EX13 Gilteritinib
:L01EX14 Entrectinib
:L01EX15 Pexidartinib
:L01EX18 Avapritinib
:L01EX19 Ripretinib
:L01EX22 Selpercatinib
:L01EX23 Pralsetinib
:L01EX24 Surufatinib
:L01EX25 Umbralisib
:L01EX26 Sitravatinib
:L01EX27 Capivasertib
:L01EX28 Repotrectinib
:L01EX29 Vimseltinib
:QL01EX90 Toceranib
<span class="anchor" id="L01F"></span>L01F Monoclonal antibodies and antibody drug conjugates
<span class="anchor" id="L01FA"></span>L01FA CD20 (clusters of differentiation 20) inhibitors
:L01FA01 Rituximab
:L01FA02 Ofatumumab
:L01FA03 Obinutuzumab
<span class="anchor" id="L01FB"></span>L01FB CD22 (clusters of differentiation 22) inhibitors
:L01FB01 Inotuzumab ozogamicin
:L01FB02 Moxetumomab pasudotox
<span class="anchor" id="L01FC"></span>L01FC CD38 (clusters of differentiation 38) inhibitors
:L01FC01 Daratumumab
:L01FC02 Isatuximab
<span class="anchor" id="L01FD"></span>L01FD HER2 (human epidermal growth factor receptor 2) inhibitors
:L01FD01 Trastuzumab
:L01FD02 Pertuzumab
:L01FD03 Trastuzumab emtansine
:L01FD04 Trastuzumab deruxtecan
:L01FD05 Trastuzumab duocarmazine
:L01FD06 Margetuximab
:L01FD07 Zanidatamab
<span class="anchor" id="L01FE"></span>L01FE EGFR (epidermal growth factor receptor) inhibitors
:L01FE01 Cetuximab
:L01FE02 Panitumumab
:L01FE03 Necitumumab
<span class="anchor" id="L01FF"></span>L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors
:L01FF01 Nivolumab
:L01FF02 Pembrolizumab
:L01FF03 Durvalumab
:L01FF04 Avelumab
:L01FF05 Atezolizumab
:L01FF06 Cemiplimab
:L01FF07 Dostarlimab
:L01FF08 Prolgolimab
:L01FF09 Tislelizumab
:L01FF10 Retifanlimab
:L01FF11 Sugemalimab
:L01FF12 Serplulimab
:L01FF13 Toripalimab
:L01FF14 Camrelizumab
:L01FF15 Envafolimab
:L01FF16 Sasanlimab
<span class="anchor" id="L01FG"></span>L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors
:L01FG01 Bevacizumab
:L01FG02 Ramucirumab
<span class="anchor" id="L01FX"></span>L01FX Other monoclonal antibodies and antibody drug conjugates
:L01FX01 Edrecolomab
:L01FX02 Gemtuzumab ozogamicin
:L01FX03 Catumaxomab
:L01FX04 Ipilimumab
:L01FX05 Brentuximab vedotin
:L01FX06 Dinutuximab beta
:L01FX07 Blinatumomab
:L01FX08 Elotuzumab
:L01FX09 Mogamulizumab
:L01FX10 Olaratumab
:L01FX11 Bermekimab
:L01FX12 Tafasitamab
:L01FX13 Enfortumab vedotin
:L01FX14 Polatuzumab vedotin
:L01FX15 Belantamab mafodotin
:L01FX16 Oportuzumab monatox
:L01FX17 Sacituzumab govitecan
:L01FX18 Amivantamab
:L01FX19 Sabatolimab
:L01FX20 Tremelimumab
:L01FX21 Naxitamab
:L01FX22 Loncastuximab tesirine
:L01FX23 Tisotumab vedotin
:L01FX24 Teclistamab
:L01FX25 Mosunetuzumab
:L01FX26 Mirvetuximab soravtansine
:L01FX27 Epcoritamab
:L01FX28 Glofitamab
:L01FX29 Talquetamab
:L01FX31 Zolbetuximab
:L01FX32 Elranatamab
:L01FX33 Tarlatamab
:L01FX34 Odronextamab
:L01FX35 Datopotamab deruxtecan
:L01FX36 Patritumab deruxtecan
:L01FX37 Linvoseltamab
:L01FX38 Ifinatamab deruxtecan
:L01FX39 Bemarituzumab
<span class="anchor" id="L01FY"></span>L01FY Combinations of monoclonal antibodies and antibody drug conjugates
:L01FY01 Pertuzumab and trastuzumab
:L01FY02 Nivolumab and relatlimab
:L01FY03 Prolgolimab and nurulimab
<span class="anchor" id="L01X"></span>L01X Other antineoplastic agents
<span class="anchor" id="L01XA"></span>L01XA Platinum compounds
:L01XA01 Cisplatin
:L01XA02 Carboplatin
:L01XA03 Oxaliplatin
:L01XA04 Satraplatin
:L01XA05 Polyplatillen
<span class="anchor" id="L01XB"></span>L01XB Methylhydrazines
:L01XB01 Procarbazine
<span class="anchor" id="L01XD"></span>L01XD Sensitizers used in photodynamic/radiation therapy
:L01XD01 Porfimer sodium
:L01XD03 Methyl aminolevulinate
:L01XD04 Aminolevulinic acid
:L01XD05 Temoporfin
:L01XD06 Efaproxiral
:L01XD07 Padeliporfin
<span class="anchor" id="L01XF"></span>L01XF Retinoids for cancer treatment
:L01XF01 Tretinoin
:L01XF02 Alitretinoin
:L01XF03 Bexarotene
<span class="anchor" id="L01XG"></span>L01XG Proteasome inhibitors
:L01XG01 Bortezomib
:L01XG02 Carfilzomib
:L01XG03 Ixazomib
<span class="anchor" id="L01XH"></span>L01XH Histone deacetylase (HDAC) inhibitors
:L01XH01 Vorinostat
:L01XH02 Romidepsin
:L01XH03 Panobinostat
:L01XH04 Belinostat
:L01XH05 Entinostat
:L01XH06 Tucidinostat
:L01XH07 Resminostat
<span class="anchor" id="L01XJ"></span>L01XJ Hedgehog pathway inhibitors
:L01XJ01 Vismodegib
:L01XJ02 Sonidegib
:L01XJ03 Glasdegib
<span class="anchor" id="L01XK"></span>L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
:L01XK01 Olaparib
:L01XK02 Niraparib
:L01XK03 Rucaparib
:L01XK04 Talazoparib
:L01XK05 Veliparib
:L01XK06 Pamiparib
:L01XK07 Senaparib
:L01XK52 Niraparib and abiraterone
<span class="anchor" id="L01XL"></span>L01XL Antineoplastic cell and gene therapy
:L01XL01 Sitimagene ceradenovec
:L01XL02 Talimogene laherparepvec
:L01XL03 Axicabtagene ciloleucel
:L01XL04 Tisagenlecleucel
:L01XL05 Ciltacabtagene autoleucel
:L01XL06 Brexucabtagene autoleucel
:L01XL07 Idecabtagene vicleucel
:L01XL08 Lisocabtagene maraleucel
:L01XL09 Tabelecleucel
:L01XL10 Nadofaragene firadenovec
:L01XL11 Lifileucel
:L01XL12 Obecabtagene autoleucel
<span class="anchor" id="L01XM"></span>L01XM Isocitrate dehydrogenase (IDH) inhibitors
:L01XM01 Enasidenib
:L01XM02 Ivosidenib
:L01XM03 Olutasidenib
:L01XM04 Vorasidenib
<span class="anchor" id="L01XU"></span>L01XU Other antineoplastic agents (cont.)
:Empty group
<span class="anchor" id="L01XX"></span>L01XX Other antineoplastic agents
:L01XX01 Amsacrine
:L01XX02 Asparaginase
:L01XX03 Altretamine
:L01XX05 Hydroxycarbamide
:L01XX07 Lonidamine
:L01XX08 Pentostatin
:L01XX10 Masoprocol
:L01XX11 Estramustine
:L01XX16 Mitoguazone
:L01XX18 Tiazofurine
:L01XX23 Mitotane
:L01XX24 Pegaspargase
:L01XX27 Arsenic trioxide
:L01XX29 Denileukin diftitox
:L01XX33 Celecoxib
:L01XX35 Anagrelide
:L01XX36 Oblimersen
:L01XX40 Omacetaxine mepesuccinate
:L01XX41 Eribulin
:L01XX44 Aflibercept
:L01XX46 Olaparib
:L01XX52 Venetoclax
:L01XX53 Vosaroxin
:L01XX57 Plitidepsin
:L01XX58 Epacadostat
:L01XX66 Selinexor
:L01XX67 Tagraxofusp
:L01XX69 Lurbinectedin
:L01XX72 Tazemetostat
:L01XX73 Sotorasib
:L01XX74 Belzutifan
:L01XX75 Tebentafusp
:L01XX77 Adagrasib
:L01XX78 Navitoclax
:L01XX79 Eflornithine
:L01XX80 Imetelstat
:L01XX81 Nirogacestat
:L01XX82 Darinaparsin
:L01XX83 Para-toluenesulfonamide
:L01XX84 Pelabresib
:L01XX85 Idroxioleic acid
:L01XX86 Calaspargase pegol
:L01XX87 Revumenib
:QL01XX91 Tigilanol tiglate
:QL01XX92 Verdinexor
<span class="anchor" id="L01XY"></span>L01XY Combinations of antineoplastic agents
:L01XY01 Cytarabine and daunorubicin
:L01XY04 Bifikafusp alfa and onfekafusp alfa